• Presented in SABCS – 2025

  • Collaborator: Novartis

  • Authors: Hope S. Rugo, Megan-Claire Chase, Megan Rutt, Mary Lou Smith, Sue Weldon, Emilie Pain, Gaurav Vadnerkar, Tamalika Sen, Shiva Padhi, Nimisha Nadimpalli, Liz Santarsiero, Corinth Auld, Nadia Harbeck, Anees B. Chagpar

Patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2– negative (HER2−) early breast cancer (EBC) remain at risk of early (≤5 years) and late (>5 years) disease recurrences despite standard-of-care adjuvant endocrine therapy.

Up to 27% of all patients with BC will recur within 10 years of diagnosis, particularly if initially diagnosed at stage II or III where recurrence rates are 41% and 63%, respectively. Currently, there is little published evidence related to the concerns of patients and caregivers concerning risk of recurrence (ROR). Lack of awareness about ROR has considerable impact on patient and caregiver quality of life, which may result in emotional distress from being unprepared about the true ROR.
Here, we present important insights on ROR through the combined results of an online patient survey and subsequent social media analysis (SMA) of patients and caregivers.